Zhao, H., Huang, X., Huang, Z., Ji, J., Zheng, L., Lu, Y., Zheng, X., Zeng, Y., Luo, J., Zhang, Y., Lu, J., Du, P., Zhang, W., Chen, B., Du, S., Zhou, J. (2026). First-in-human phase I/II study of MRG006A, a first-in-class Glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3028